Loading...
•
Sep 30, 2023
Amphastar Q3 2023 Earnings Report
Amphastar reported strong results driven by the success of its diabetes portfolio and the strategic acquisition of BAQSIMI.
Key Takeaways
Amphastar Pharmaceuticals reported net revenues of $180.6 million for the three months ended September 30, 2023. GAAP net income was $49.2 million, or $0.91 per share, and adjusted non-GAAP net income was $61.9 million, or $1.15 per share.
Net revenues for the third quarter were $180.6 million.
GAAP net income for the third quarter was $49.2 million, or $0.91 per share.
Adjusted non-GAAP net income for the third quarter was $61.9 million, or $1.15 per share.
Glucagon sales increased due to an increase in unit volumes.
Revenue by Segment
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...